<SEC-DOCUMENT>0001129928-12-000052.txt : 20120816
<SEC-HEADER>0001129928-12-000052.hdr.sgml : 20120816
<ACCEPTANCE-DATETIME>20120816124517
ACCESSION NUMBER:		0001129928-12-000052
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20120816
FILED AS OF DATE:		20120816
DATE AS OF CHANGE:		20120816

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		121039389

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6-k.htm
<DESCRIPTION>6K FORM
<TEXT>
<html>
<head>
    <title>form6-k.htm</title>
    <!--Licensed to: Oncolytics Biotech Inc-->
    <!--Document Created using EDGARizer 2020 5.4.3.1-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<br>
<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Washington, D.C. 20549</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">Form 6-K</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Report of Foreign Private Issuer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Pursuant to Rule&#160;13a-16 or 15d-16</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">of the Securities Exchange Act of 1934</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the month of&#160;August 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Commission File Number 000-31062</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Oncolytics Biotech Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">__________________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Translation of registrant&#8217;s name into English)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Suite&#160;210, 1167 Kensington Crescent NW</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Calgary, Alberta, Canada T2N 1X7</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">__________________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;(Address of principal executive offices)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant files or will file annual reports under cover Form&#160;20-F or Form&#160;40-F.</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Form&#160;20-F&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">&#254;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Form&#160;40-F&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(1):&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Note: </font>Regulation&#160;S-T Rule&#160;101(b)(1) only permits the submission in paper of a Form&#160;6-K if submitted solely to provide an attached annual report to security holders.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(7):&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Note: </font>Regulation&#160;S-T Rule&#160;101(b)(7) only permits the submission in paper of a Form&#160;6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on which the registrant&#8217;s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant&#8217;s security holders, and, if discussing a material event, has already been the subject of a Form&#160;6-K submission or other Commission filing on EDGAR.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&#160;12g3-2(b) under the Securities Exchange Act of 1934.</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Yes&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">No&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">&#254;</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If &#8220;Yes&#8221; is marked, indicate below the file number assigned to the registrant in connection with Rule&#160;12g3-2(b):&#160;&#160;&#160;82&#160;-&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">EXHIBIT</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NUMBER</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="69%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">DESCRIPTION</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="69%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">99.1</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="69%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">News Release Dated August 16, 2012: Oncolytics Biotech&#174; Inc. Completes Patient Enrollment in U.S. Phase I Clinical Trial Investigating REOLYSIN&#174; in Combination with FOLFIRI in Patients with Colorectal Cancer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="4" valign="top" width="39%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Oncolytics Biotech Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Registrant)</font></div>
</td>
</tr><tr>
<td align="left" valign="middle" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="middle" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="middle" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="middle" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Date:&#160;&#160;August 16, 2012</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="36%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/&#160;&#160;Doug Ball</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Doug Ball</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Chief Financial Officer</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<br>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1 CHARTER
<SEQUENCE>2
<FILENAME>ex99.htm
<DESCRIPTION>RELEASE
<TEXT>
<html>
<head>
    <title>ex99.htm</title>
    <!--Licensed to: Oncolytics Biotech Inc-->
    <!--Document Created using EDGARizer 2020 5.4.3.1-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<br>
<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font><br>
&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">210, 1167 Kensington Cr. N.W.</font></div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Calgary, Alberta</font></div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Canada T2N 1X7</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><img src="onclogo.jpg" alt=""></div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -18pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FOR IMMEDIATE RELEASE</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Oncolytics Biotech<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font> Inc. Completes Patient Enrollment in U.S. Phase I Clinical Trial Investigating REOLYSIN<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font> in Combination with FOLFIRI in Patients with Colorectal Cancer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">CALGARY, AB, --- August 16, 2012</font> - Oncolytics Biotech Inc. (&#8220;Oncolytics&#8221;) (TSX:ONC, NASDAQ:ONCY) today announced that it has completed patient enrollment in its U.S. Phase I clinical trial using REOLYSIN in combination with FOLFIRI (Folinic Acid (leucovorin) with Fluorouracil (5-FU) and Irinotecan) in patients with oxaliplatin refractory, Kras mutant colorectal cancer (REO 022).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The trial is a 21-patient, single arm dose escalation study designed to determine a maximum tolerated dose and dose-limiting toxicities for the combination of REOLYSIN and FOLFIRI.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Eligible patients include those with histologically confirmed cancer of the colon or rectum with Kras mutation and measurable disease. They must have progressed on or within one hundred and ninety days after the last dose of an oxaliplatin regimen in the metastatic setting, or be intolerant to oxaliplatin.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The principal investigator for the study is Dr. Sanjay Goel of the Montefiore Medical Center at the Albert Einstein College of Medicine in New York.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;We are pleased to complete enrollment in this clinical study as we learn more about using REOLYSIN for the treatment of colorectal cancer,&#8221; said Dr. Brad Thompson, President and CEO of Oncolytics. &#8220;Oncolytics continues to expand its colorectal cancer program and we recently announced entry into an agreement where the NCIC Clinical Trials Group would conduct an open-label, randomized, non-blinded, Phase II clinical study of REOLYSIN given in combination with FOLFOX-6 plus bevacizumab (Avastin) versus FOLFOX-6 plus bevacizumab alone.&#8221;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About Oncolytics Biotech Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics&#8217; clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.oncolyticsbiotech.com</font>.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company&#8217;s expectations related to the U.S. Phase I clinical trial investigating REOLYSIN in combination with FOLFIRI in patients with colorectal cancer, and the Company&#8217;s belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company&#8217;s actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the tolerability of REOLYSIN outside a controlled test, the success and timely completion of clinical studies and trials, the Company&#8217;s ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company&#8217;s quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FOR FURTHER INFORMATION PLEASE CONTACT:</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Equicom Group</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Nick Hurst</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">300 5<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font> Ave. SW, 10<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font> Floor</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Calgary, Alberta, T2P 3C4</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Tel: 403.218.2835</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fax: 403.218.2830</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">nhurst@equicomgroup.com</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</td>
<td align="left" valign="top" width="31%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">IRG, LLC</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Tom Caden</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">20th Floor, 1251 Avenue of the Americas</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">New York, NY&#160;&#160;10020</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Tel:&#160;&#160;212.825.3210</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fax:&#160;&#160;212.825.3229</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">tcaden@investorrelationsgroup.com</font></font></div>
</td>
<td valign="top" width="23%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-30-</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<br>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>onclogo.jpg
<TEXT>
begin 644 onclogo.jpg
M_]C_X``02D9)1@`!`0$!+`$L``#_X0E(17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````0````<@$R``(````4````@H=I``0````!````E@```+8```$L````
M`0```2P````!4&%I;G0N3D54('8U+C`P`#(P,#@Z,#4Z,C(@,34Z,CDZ,S@`
M``*@`@`$`````0```\"@`P`$`````0```.$`````````!@$#``,````!``8`
M``$:``4````!```!!`$;``4````!```!#`$H``,````!``(```(!``0````!
M```!%`("``0````!```(+`````````!(`````0```$@````!_]C_X``02D9)
M1@`!`@$`2`!(``#_[0`,061O8F5?0TT``?_N``Y!9&]B90!D@`````'_VP"$
M``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43$Q@1#`P,#`P,$0P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-$`X.$!0.#@X4%`X.#@X4$0P,
M#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(
M`"8`H`,!(@`"$0$#$0'_W0`$``K_Q`$_```!!0$!`0$!`0`````````#``$"
M!`4&!P@)"@L!``$%`0$!`0$!``````````$``@,$!08'"`D*"Q```00!`P($
M`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#
M!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$
MU.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0`"`@$"!`0#!`4&
M!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S
M-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6U
MQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@`,`P$``A$#$0`_`/55C]2^
ML3,?,_9O3\=_4^I@!S\>DAK:VGZ+LS)?^BQMWYG^%_X-%^L?4KNF])MOQFA^
M786T8C#WNN<*:/\`->_U%/HG1Z.D8+<:LFVYY-F5DNU?=<[W77VN^DYSW)I)
M)H:=RIH[_KT[WBKI=0.OI.?>YP_DNM:QK/\`P-*GZRW8V37A]?PSTRVXAE&2
M'BW%L<>*VY(#/1M?^95D,8MY`S<+%S\6W#S*VW8][=ME;N"#_K[7)<)&Q/U4
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M[/HUTX=3_.R+K?\`HUVUK*HQ.HGK?7.H=),9^+E,!Q["6U9-+J:G.Q7S[:K=
M_OQLK_!6?SGZ&Q=!]7^E6=,P7-R;!=G95CLG.N:(#KK/I[/^"K;MJJ_X-B:K
MK+[,_P"QG%>T>M91ZG,>FSU6W/9M]M-WT&6?03*T%Z:D_P",EH?5&]F3D]:R
M:V65-NS`[T[FEEC3Z-#;*[*W?1?7:U]:I=-_98R,P?6P5?M0WV;'9X'H^A/Z
MN.FNR?U;[/L^DVG]-ZG])]ZZG)R319C,%;K/M-OI%S>&#T[;O4?_`"/T/I_]
M<4<_+=B8_K-J=<2]C(;PT/<&>K:[W;**MWJ76;?T=:/#IO\`+X:*<SJ0>[ZJ
MY#?JN&L=Z3AB#'`9^=^E^S_1VV?SOI?\(L[_`+!3TN"RAEVSZ&V.H"R/W?\`
ME'[=ZG_7O4718.<[+?>PU%@H>&BUIW56`M;9NHMAGJ;-WIV^S^=3?:\G]I?8
M_0'I>GZOK[C$3LV;?3V^K_(]3Z"1`-'3]W93S^8WJCO\7%S>J!YSSAN%H?K9
MW]/U-O\`A?2V>I_PBV>F=9Z3>S'Q*,RFS(-;0*FO!<2UNY_M^E[6M1^I=0=@
MMH(I-WKV^D2#`8-EEWJ6.AWM_0^G_7L5JI_J5L?I[FAVAD:C\UVB(%'0[`#5
M3S'7,;)Z+E5Y?1+1C.ZSD,Q,FES/4J;==(KZI75+?3R*MOZ?_`Y?^&_2+8P.
MA=.PL!^#Z8R*[B7Y3\B+'WV.ULNRG/\`YU[W?^HT3IW479K0\UBC<W=Z+W'U
MF:QLR*-GZ&S]_P#2V(N5E.Q[,9C:7W?:+342R/8!7;?ZC]WMV?H?3_ZXD`-3
MT*GG>G=%Z/9]9NLX]F!COHJKQ#56ZEA8TO;=ZOI,<WTV[]OZ38K7UI'ZWT"!
MQU*O@<?H[_!;&!E.S,87NJ?02^QGIV:.'IO?3+OZ_I[U80$1PT.NO_=*>;^L
MF_\`:N`>HA[OJ^&O^TA@<:_7D>A^T&U>[['_`%_U;U?Z0KW2S]6/M3OV.,3[
M0:_>[$#/H`C1[Z!M^G^8KV/E&[(RJ36Y@QGM8'NX?NKKNWL_J^KZ?]A4^H]:
MLP+KV?8[KZZ:&W"VL%P+WFYM>/M:USO=Z'\[[_2]6OUO39[TM`>+]BGGLRGH
M[,_.O;G]-R;;+7.MHZO6'VL</8ZC&O=978S$;M_0U?9K_P#@UT'U9O%_1Z7M
MP?V:P%[68^H;M#C%M(<VJST;OYROU*JE=SLHX>*_(%3[RR/T=8EWN<&;O^+K
MW>I;_P`$I8MYOK+SZ9@Q^B?ZC?\`/V5I"-2W_!3_`/_1]56;U[]@_8'?M[T/
ML<_]J(C=_P`%^?ZO_%?I%\SI(2V.WUV4^Z,H^J3JM^-D]79A]JZAU'T8_D_H
MG>S^VMKZL_\`-3T[/^;_`*.^?T\3Z_\`Z$?:/UO_`+=7SBDHX[CY?I_W*?M?
MJI)?*J2E0_522^54DE/U4DOE5))3]5)+Y5224_522^54DE/U4DOE5))3]5)+
MY5224_522^54DE/_V?_B#%A)0T-?4%)/1DE,10`!`0``#$A,:6YO`A```&UN
M=')21T(@6%E:(`?.``(`"0`&`#$``&%C<W!-4T94`````$E%0R!S4D="````
M``````````````#VU@`!`````-,M2%`@(```````````````````````````
M````````````````````````````````````$6-P<G0```%0````,V1E<V,`
M``&$````;'=T<'0```'P````%&)K<'0```($````%')865H```(8````%&=8
M65H```(L````%&)865H```)`````%&1M;F0```)4````<&1M9&0```+$````
MB'9U960```-,````AG9I97<```/4````)&QU;6D```/X````%&UE87,```0,
M````)'1E8V@```0P````#')44D,```0\```(#&=44D,```0\```(#&)44D,`
M``0\```(#'1E>'0`````0V]P>7)I9VAT("AC*2`Q.3DX($AE=VQE='0M4&%C
M:V%R9"!#;VUP86YY``!D97-C`````````!)S4D="($E%0S8Q.38V+3(N,0``
M````````````$G-21T(@245#-C$Y-C8M,BXQ````````````````````````
M``````````````````````````````````````````!865H@````````\U$`
M`0````$6S%A96B``````````````````````6%E:(````````&^B```X]0``
M`Y!865H@````````8ID``+>%```8VEA96B`````````DH```#X0``+;/9&5S
M8P`````````6245#(&AT='`Z+R]W=W<N:65C+F-H```````````````6245#
M(&AT='`Z+R]W=W<N:65C+F-H````````````````````````````````````
M`````````````````````````&1E<V,`````````+DE%0R`V,3DV-BTR+C$@
M1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@``````````````+DE%
M0R`V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@``
M``````````````````````````!D97-C`````````"Q2969E<F5N8V4@5FEE
M=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ```````````````L4F5F
M97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``````
M````````````````````````````=FEE=P``````$Z3^`!1?+@`0SQ0``^W,
M``03"P`#7)X````!6%E:(```````3`E6`%````!7'^=M96%S``````````$`
M```````````````````````"CP````)S:6<@`````$-25"!C=7)V````````
M!``````%``H`#P`4`!D`'@`C`"@`+0`R`#<`.P!``$4`2@!/`%0`60!>`&,`
M:`!M`'(`=P!\`($`A@"+`)``E0":`)\`I`"I`*X`L@"W`+P`P0#&`,L`T`#5
M`-L`X`#E`.L`\`#V`/L!`0$'`0T!$P$9`1\!)0$K`3(!.`$^`44!3`%2`5D!
M8`%G`6X!=0%\`8,!BP&2`9H!H0&I`;$!N0'!`<D!T0'9`>$!Z0'R`?H"`P(,
M`A0"'0(F`B\".`)!`DL"5`)=`F<"<0)Z`H0"C@*8`J("K`*V`L$"RP+5`N`"
MZP+U`P`#"P,6`R$#+0,X`T,#3P-:`V8#<@-^`XH#E@.B`ZX#N@/'`],#X`/L
M`_D$!@03!"`$+00[!$@$501C!'$$?@2,!)H$J`2V!,0$TP3A!/`$_@4-!1P%
M*P4Z!4D%6`5G!7<%A@66!:8%M07%!=4%Y07V!@8&%@8G!C<&2`99!FH&>P:,
M!IT&KP;`!M$&XP;U!P<'&0<K!ST'3P=A!W0'A@>9!ZP'OP?2!^4'^`@+"!\(
M,@A&"%H(;@B"")8(J@B^"-((YPC["1`))0DZ"4\)9`EY"8\)I`FZ"<\)Y0G[
M"A$*)PH]"E0*:@J!"I@*K@K%"MP*\PL+"R(+.0M1"VD+@`N8"[`+R`OA"_D,
M$@PJ#$,,7`QU#(X,IPS`#-D,\PT-#28-0`U:#70-C@VI#<,-W@WX#A,.+@Y)
M#F0.?PZ;#K8.T@[N#PD/)0]!#UX/>@^6#[,/SP_L$`D0)A!#$&$0?A";$+D0
MUQ#U$1,1,1%/$6T1C!&J$<D1Z!('$B8211)D$H02HQ+#$N,3`Q,C$T,38Q.#
M$Z03Q1/E%`84)Q1)%&H4BQ2M%,X4\!42%3055A5X%9L5O17@%@,6)A9)%FP6
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MUS@4.%`XC#C(.04Y0CE_.;PY^3HV.G0ZLCKO.RT[:SNJ.^@\)SQE/*0\XSTB
M/6$]H3W@/B`^8#Z@/N`_(3]A/Z(_XD`C0&1`ID#G02E!:D&L0>Y",$)R0K5"
M]T,Z0WU#P$0#1$=$BD3.11)%546:1=Y&(D9G1JM&\$<U1WM'P$@%2$M(D4C7
M21U)8TFI2?!*-TI]2L1+#$M32YI+XDPJ3'),NDT"34I-DTW<3B5.;DZW3P!/
M24^33]U0)U!Q4+M1!E%049M1YE(Q4GQ2QU,34U]3JE/V5$)4CU3;52A5=57"
M5@]67%:I5O=71%>25^!8+UA]6,M9&EEI6;A:!UI66J9:]5M%6Y5;Y5PU7(9<
MUETG77A=R5X:7FQ>O5\/7V%?LV`%8%=@JF#\84]AHF'U8DEBG&+P8T-CEV/K
M9$!DE&3I93UEDF7G9CUFDF;H9SUGDV?I:#]HEFCL:4-IFFGQ:DAJGVKW:T]K
MIVO_;%=LKVT(;6!MN6X2;FMNQ&\>;WAOT7`K<(9PX'$Z<95Q\')+<J9S`7-=
M<[AT%'1P=,QU*'6%=>%V/G:;=OAW5G>S>!%X;GC,>2IYB7GG>D9ZI7L$>V-[
MPGPA?(%\X7U!?:%^`7YB?L)_(W^$?^6`1X"H@0J!:X'-@C""DH+T@U>#NH0=
MA("$XX5'A:N&#H9RAM>'.X>?B`2(:8C.B3.)F8G^BF2*RHLPBY:+_(QCC,J-
M,8V8C?^.9H[.CS:/GI`&D&Z0UI$_D:B2$9)ZDN.339.VE""4BI3TE5^5R98T
MEI^7"I=UE^"83)BXF229D)G\FFB:U9M"FZ^<')R)G/>=9)W2GD">KI\=GXN?
M^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16I,>E.*6IIAJFBZ;]IVZGX*A2J,2I-ZFI
MJARJCZL"JW6KZ:Q<K-"M1*VXKBVNH:\6KXNP`+!UL.JQ8+'6LDNRPK,XLZZT
M);2<M1.UBK8!MGFV\+=HM^"X6;C1N4JYPKH[NK6[+KNGO"&\F[T5O8^^"KZ$
MOO^_>K_UP'#`[,%GP>/"7\+;PUC#U,11Q,[%2\7(QD;&P\=!Q[_(/<B\R3K)
MN<HXRK?+-LNVS#7,M<TUS;7.-LZVSS?/N-`YT+K1/-&^TC_2P=-$T\;42=3+
MU4[5T=95UMC77-?@V&38Z-ELV?':=MK[VX#<!=R*W1#=EMX<WJ+?*=^OX#;@
MO>%$X<SB4^+;XV/CZ^1SY/SEA.8-YI;G'^>IZ#+HO.E&Z=#J6^KEZW#K^^R&
M[1'MG.XH[K3O0._,\%CPY?%R\?_RC/,9\Z?T-/3"]5#UWO9M]OOWBO@9^*CY
M./G'^E?ZY_MW_`?\F/TI_;K^2_[<_VW____;`$,``@$!`@$!`@("`@("`@(#
M!0,#`P,#!@0$`P4'!@<'!P8'!P@)"PD("`H(!P<*#0H*"PP,#`P'"0X/#0P.
M"PP,#/_;`$,!`@("`P,#!@,#!@P(!P@,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(`'`!X`,!(@`"$0$#
M$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_Q`"U$``"`0,#
M`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S
M8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H
M:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ
MPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q``?`0`#
M`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($!`,$!P4$!``!
M`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q
M%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X
M>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(
MR<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$``A$#$0`_`/W\
MHHHH`****`"BL/XB?$G0_A/X6NM<\2:KI^BZ/9+OGN[R=88HQ]6/4]`!R3P*
M^!/VE_\`@X"\+^%+FXTWX9>')O%%Q'E!JFI,UK99_O)$/WLB_7R\]LUP8S,L
M/A5>M*WEU+A!R=D?HO17X?:K_P`%._VIOVE=5EM_#.H:RBR'_CQ\*Z(&*9[!
MU1Y0.G5\TZ+P!^V]KZBY$GQY42<X.JWMO_XZ9%Q^5>1_K-"6M*C.2]#3V#ZL
M_;^BOPYNOB'^VG\"5-W>W'QHMH(?F::_M[G48%'N95D3'UKN/@O_`,%\?BGX
M#OH[3QQHFB^,+.,[9F$7]G7P['YD!CXYX,8/OWHI\3X?FY:T)0]4'U=O9G['
M45\Y_LF?\%0?A7^UT\.GZ/JCZ)XEE'_(%U7;!<R''(B;)24=?N$MCD@5]&5[
M]#$TZT%.E*Z,91:=F%%%%;B"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"O$_VVOVY/"?[$?PT&M:^_P!MU6^#
M1Z3I$#@7&HR@?^.QKD%G(P!P,L0I[;]H?X\Z'^S1\(-;\:>(YO*TO1;<RLJD
M>9<2'B.%`>KNQ"CW//&37XJ^$/#/Q$_X*_?MEW%Q=W$D$=PWFW=Q@O:^'M.5
MOEC0>N#M5>"[DL>K,/"SC-)4.6C05ZDMEV\V;4J:E=RV0[6/$'QR_P""OWQR
M^S6Z37UO;2;TM8W:#1O#\).`S'D`XS\QW2/@@9X`_0/]DW_@B#\,O@G8VNH>
M-4'Q!\1H`S_:U*:;"_HD&?G'O*6!Z[17T[^SA^S;X4_99^&%EX3\(:?'9:?:
MJ#+*0#/>RX^::5OXG;UZ`8````'?5E@,@IP_?8KWZCU=]E\ASKMZ0T1G^&?"
MNF^#=)CL-)T^QTRQA&([>T@6&)!Z!5``K0HHKZ",4E9&`5Y7\>?V*?AA^TOI
M\L/C#PAH^IW$@(%\D(@O8O=9TPX]<$D'N#7JE%34I0J+EFDUYC3:V/QY_;8_
MX(D>*_@1%/XJ^%EYJ'BS0[,^>]@1C5K``[MZ;,"8+@'*@.,?=.,UUG_!-?\`
MX+,WWAG4['P%\8[Z2[T^1UM;#Q'<']_9-G`CNR>63/'FGYE_BR,LOZM5^<W_
M``5W_P""6-IX[T/4OBE\.M.6#Q):(]WKNE6T>%U6,#+7$:CI,O5@!^\&3C?]
M[Y?&974P4OK6`?K'HT=$*JG[DS]%+*\CO[9)HG22*50Z.C;E=3R"#W!'.:EK
M\Q?^"(O_``4,GU&:#X,>,;UIYDC)\,7D[Y9E526LF8]<*"T>>P9>R"OTZKWL
MNQ\,715:'S79]C&<'%V84445W$!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`445#J.H1:7937$[K'#`C2.QX"JHR3^5#8'Y)
M_P#!>W]J>?QM\6])^%&EW#MIOA=4O]42,G$][*N8T('79"P(]YCW6ON+_@F%
M^QS;_L@_LS:;8W5NB>*_$*)J>NS%1O$K+E(,_P!V)3MQTW;S_%7Y?_L8:+-^
MW)_P5/LM:U6,W-GJ&OW7BB]63+*L,+/-'&?]G<(8\>AQ7[H5\IDE-8K$5<PG
MWM'R2.BJ^6*@@HHHKZLYPHHHH`****`"D90X((!!]:6B@#\1_P#@JW^S#=?L
M2_M>Z?XO\(>9I.C^)+C^W-(EMUV+I][%('EB3'0*^V11T"R;<84U^MG[(G[0
M%I^U!^SOX6\<6HCC?6K-6NH4.1;W*$I/']%D5P,]1@]Z\2_X+6_!*'XM_L-:
MWJ*0B34?!5Q%K5LP'S!%/ES#/IY4CL?=%]*\7_X-X/B_)JOPR\>^![B8L-$O
MH-6M%)Z)<(T<BCT`:!3]9*^3PL?J>:2PZ^"HKI>?]7.B7OTU)[H_2&BBLSQ3
MXQTCP59QW.LZIIVDVTC^6LMY<I`C-C.T%R`3P>/:OJY225V<YIT5C^%OB%H7
MCD3_`-BZUI&K?9L>;]CO([CR\YQNV$XS@]:V*4)J2NG<`HK)\6>.=%\#P0RZ
MUJVF:1%.Q6-[VZ2W5R!D@%R,G'/%6?#WB.P\5Z7'?:9>V>H64V?+GM9EFB?!
M(.&4D'!!'![4*2O8"[1115`%5-.EOWO-0%Y!:16Z3@630S-(\T/E1DM("JA'
M\TRKM4N-JHVX%BJUO%?C71_!-C]JUG5=.TJV'_+6\N4@3\V(%</_`,-C?";[
M7Y/_``LGP*)<XV_VY;9SZ??K*=:G%VE)+YC29Z9165X4\;Z-XVM#<:-JNFZK
M`/\`EI9W23K^:$BM6KC)-70@HHS61XL\=Z+X&LA<ZUJVF:3;G_EI>726Z?FQ
M`HE))78&O17F2_MD_"5[CRA\2O`ID)QC^W+;KZ??KN/"WC;1O&UA]JT;5--U
M6V/_`"UL[E)T_-2140KTY.T9)_,=GU-6BC-%:B"BL3Q/\1_#_@B6&/6M<T;1
MY+@%HEO;V.W,@'4J'(SC/;UK2T?6+77].AO+*XM[RTN%#Q3P2"2.53T*L."/
M<5$9IZ7U`LT4458!17)ZM\>/!7A[5)['4?%WAC3[VU;9+;W&J012Q-C.&5F!
M!P1U]:Z:PU"'4[2.XMY8IX)E#QR1N&1U(R""."".XJ(U(RT3`FHHK(\5>/M#
M\#QP/K6L:5I*7)(B:]NX[<2$#)`+D9P/2G.:BKL#7HK,\*^,=)\:V+W6C:GI
MVJVT;^6TMG<I.BMC.TE20#@@X]ZJ^)?B=X<\%W4=OK.OZ+I$\R>9''>7T5N[
MKDC<`[`D9!&12=2*5V]`-VBN1_X7_P"!?^AT\)?^#BW_`/BZ/^%_^!?^AT\)
M?^#BW_\`BZGV]/\`F0['745R/_"__`G_`$.GA/\`\&]O_P#%UU-E>QZA;1SP
MR1RPRJ'1T8,KJ1D$$<$$=ZJ%2,OA=PL2T53U_P`0V/A729K_`%*\M-/L;9=T
MMQ<RK%%$,@99F(`&2!R>]4?!_P`1_#_Q`6X.A:[H^M"TVB8V-Y'<>5NSC=L)
MQG!QGKBAS2:BWJ(VJ***L`HJEKWB33_"]@UUJ5]9:?;(,M+<SK#&OU9B!7`S
M_MB?">VNS!)\2?`R2J<%3KEMD'T^_6<ZT(_$TOF-)]#TNBL/P?\`$OP]\0(#
M+H>NZ/K,8`):QO([@#_O@FMRJA-25XNX@HHS7"^-?VFOAW\-+QK?Q!XX\)Z-
M<+G=%=ZK!%(/^`EL_I4U*L8:R=AV.ZHKRK2_VXO@]K4XBM?B=X&ED)P`-9@!
M)].6KT7P[XKTSQ=8K=:5J-CJ5LPR);6X29#^*DBE3KTY_!)/Y@XM;FA1116H
M@KSG]KK6I?#G[*GQ+U&`E9K#PIJEPA!P0R6<K#]17HU>>?M9Z#-XI_9;^)&E
MP*S3ZEX6U.UC`&26>TE4#\S6&)O[*7+O9_D5#XD?F!_P;S:!%??M1^,=1<`R
MV/AEHHSW7S+F#)'_`'QC\:_8*OQY_P"#>KQ+%I_[5/BW378+)J/AEY(\_P`1
MBN8,CZX<G\#7[#5XG"[7U%6[O\S7$?&%%%%?1&`4444`%%%%`!1110!P7[47
MAR/Q?^S9X_TJ5=\>H>'-0MR,9/S6T@R/?)XK\L?^#>[7'M/VMO%.G`YBO_"L
MLC#.,M'=6V#^3G\Z_4G]J[Q/%X+_`&8?B'JTS!4T_P`-ZA/UQDK;28'U)P![
MD5^7/_!O9X?>\_:N\6:G@B'3_"\D+-C(#2W5O@?DC?E7R^:_\C/#<N]W_P``
MZ*7\.1^Q%?GQ_P`'$)(_9I\$8`R?$_\`[:S5^@]?GO\`\'$?_)M/@?M_Q4__
M`+:S5Z&?O_8*GI^J,Z/QH_/WX">)OB;^Q18>$OC3X7++H.NSSV+M\SVER8I"
M)+.Y4=-RJ'4^^0<J<?M5^QE^V?X3_;6^%<7B'P[,MO>VX6/5-+E<&XTR;'*,
M.ZG!*N!AAZ$$#YC_`.".WPI\/_M!_P#!,_5/"/BK3X=5T2^UV^MYX7&",K"Z
MNIZJZL0RL,$$`U\A_''X%?$[_@CG^TG9>*_"MY<WGAB[F*6&H.A-MJ,!)+65
MVHX#X'MG`=,$87Y[`SK9?1AB(^]1DDY+JGW-ZB4VT]T?2_\`P<96[/\`"[X9
M2A0535;Q">XS#&1_Z#^E>X?\$3#G_@G7X./'_'YJ/_I;-7R-_P`%5_VLO#7[
M;?[#_P`.O&?AUS#<V'B(VFJZ<[AIM,N'M)&\M_53Y9*OT8#L00/KG_@B9_RC
MK\'8[WFI?^ELU=F#JQJ9S.I!W3@FOP(G%JE9]SZQK\\O^"K7_!6?4O@#XEN/
MAQ\.'@C\4P1C^UM6=1*-,WKN6*)3P9=I!+,"%R!@MG;^AM?SY_MHZ->>`/\`
M@H3X\_X2>*5UC\7S7TPD!)GM9+CSHV`[JT+K@#C!Q77Q)C*M##Q5)VYG9OLB
M:$%*6I]P?LP_\$==3_:%T2R\=?M`>+O%6KZQK$:W<>DB\8R01N-P6:5]S!B#
MRB!=O3.1Q]!3_P#!%K]GB;2_LP\&74;8QYZZO=B7ZY,F/TKZ>T'6[3Q'HUKJ
M%A/#=6%["D]O-$P:.:-AE64C@@@@CZU<R/45V4,FPD()."D^K>K?S)E4E?1V
M/EW]F?\`X))_#+]EGXMMXP\/WGBBZO(E*VEM>7X:WM2>"V$52YQP`Y8#TS@C
MZBHS17?A\-3H1Y*4;+R(<FW=GPG_`,%>_P#@ICJ7[*5O8^!O!#PQ>,]9M/M=
MS?NHD_LBV9BJE5/!E<JV-W"A<X)(KR?]B+_@E$_[7_@+3_BE\;?%7BC6Y_$B
M_;+'3Q>MYCV['Y))96RPWCYE5-N%*\\X'@O_``7*\,:EHG[?.KWMY'(+/6=*
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M#^'9K57,%AINH3W9`R!$;=HQGV\QXQ]2*_<>LN&\74Q&$YJKNT[7[[#Q$%&5
MD?DG_P`'%/\`R6[X=_\`8#G_`/2BOO;_`()D?\F#_"S_`+`<7_H35\$_\'%/
M_);OAW_V`Y__`$HK[U_X)D''[`_PLY`_XD<7_H35QY>_^%BOZ?Y#J/\`=(]W
MHHH!STYKZJYSGQG_`,%/?^"7&F?M=Z%+XJ\*Q6^F?$>PB^5^$AUM%'$,QZ!P
M.$D[<!LKROR1_P`$UO\`@I9K?['GC,_"CXL)?VWAFVNFLXY+Q6%SX:GW$%&!
MY,&>H_@Y8?+D5^P=?$G_``5X_P"">7A_X]_";7/B-IBP:1XT\):;-?S7*IB/
M5K:",R-#*!U<*IV/U&-IR",?.YGETZ<_KN#TFMUTDO\`,WISNN61[S^U=^VQ
MX,_9*^#R^+M<OH+R*_C_`.)19VLJO+J\A7*K%CC9@@E_NJ"#SD`_EG\*OA3\
M3_\`@M!^TS=^)?$EU<:9X1TR41W5U&I^RZ3;YRMI:J>&E(Y)/KN;L#Y7^Q;\
M$==_;^^/WA3P#K7B?48]%T*QD8/+*96L;&)M[0P*>%+,X`[#.>0H%?NW\'?@
MYX<^`GP]T[PMX5TR#2M$TN/RX8(QR3W=CU9V.26/)))-<6'=7.)*=7W:4>E]
MWY^14DJ6BW(/@?\``_PW^SM\.-.\*>$].ATS1M-C"1QJ/GE;^*1VZN['DL>2
M:\R_:G_X)O\`PR_;%\9V'B#QK9ZM/J>FV8L(7M+][=?*$C2`$#()W.QS[_2O
M>Z*^HJ86E.G[*<4X]CG3:=T?G=^V!_P1R^"WP:_9>\=^*M"LO$,.L>']&GOK
M1Y=4:5%DC7<N5(P1QT]*^3?^"0O[&'@K]L[XG>+M,\;0ZE/9Z+ID5U;K:71M
MSYC2[220,D8[>]?JW_P43_Y,5^*W?_BFKS_T6:_/S_@W5/\`Q>SXB#C_`)`E
MO_Z45\ECL#AXYG0I1@E%WNOO.JG.7LWJ?42_\$*O@`I_Y!OB?'<?VP_/Z5]>
M>'/#UKX4T*RTRPB6"QT^!+:WB7I'&BA54>P``J[17U=#!4*+;I12OV.:4V]V
M?,W_``6&_P"4<'Q([?NK#_TXVM?)G_!N*2=>^+?`R(-*_P#0KNOK/_@L-_RC
M@^)&?^>5A_Z<;6ODO_@W$S_;WQ;_`.N&E?\`H5W7SV,?_"W1_P`/^9O3_A,_
M4VOB3_@JS_P5#D_8^2V\'>#XK2\\=ZG;?:I)YQYD.CP-D*Y7^*5B#M4\`#<<
M@@'[;K\(O^"R?AG5O#__``4'\;3ZHDPBU9;.\L9'SMEM_LT48VY[*T;K]5-=
MG$>-JX;"\U'=NU^Q-""E*S/HW]DC_@F;XN_;V\-67Q.^.GCGQ3=Z?K8^TZ;I
MJW'^D3P$Y65BP*0QL.51%R5(.1G%?4MM_P`$6?V>+?3/LS>#;J9L8\^35[LR
M_7(D`S^%>T_LJ>)]+\8_LU>`]1T:6"73+C0++R#%C:@$"J4XZ%2"I'4$$=J]
M"W#U%;8/*<*J47**DVE=O5LB525]'8^2?A%_P1D^$GP5^,=AXQT:X\5^9IC>
M;;Z?-J1-LDH/RL2JJ[`?W2Q![Y'%?6U&:*]'#X6E03C2BDGV)E-O=GYF?\%W
M/VJ?B+\,O$/AWP1X>N=3\/\`A76---Y=ZC:%HGU.8NZ-;>:O(5%569006\P9
MXQ69_P`$R/\`@GQ^SW\>_@SI?B'Q)K*>-/%]\K2:CIDFJ-;'37WD>68499#Q
M@[V)#9R.*_1_XM?!OPQ\=?!\^@>+=%T_7M(N/O6]W$'4'LRGJK#LRD$=C7P]
M\6/^#?OP7K&NR:CX%\::]X/9B62UFB%]'"?1'W)(!_O,Q]Z^<QF65UBWBE%5
M8O[+=K>FZ9K":Y>78]=\4_\`!%W]GKQ-8&&+P?=:3(00)K+5;E9%]_G=E/X@
MU2_9C_X(_P#@C]EGXV1^,-$\4>,;N.U0_9]-GNQ'")#QND,07S0!T5ACN<X%
M?..J_P#!,;]JGX!V+7?P\^,5SK<=J-\=DNK7%H\@'81S%HB?8L!7,_LY_P#!
M:[XF_"7XMP^#_C+86^IV5M?_`-FZE.UH+74M,</L9F"820(W4;02`<'IF8XG
M!TJL7B<.Z;OH^E_5#Y)23Y97/ULHIL<@D4,""I&01WIU?6IG.%17MG'J%M)#
M*JO%*I1E(R&!&"/RJ6BA@?A7^S#K$G[!'_!5&TTS4Y#:Z?HWB*X\/WCR?*IM
M9R\22M_L[7BE^@%?NH"",@@@U^3O_!?7]E";P[X[T;XMZ5;,;'7$32M:9%_U
M5S&/W,S8_OQC9GL85_O5]>?\$H/VT(/VL_V:[*#4+I'\8^$8X]-UB-F_>3A5
MQ#<XZXD5>3_?5_:OD\FJ+"8FK@)][Q].QT55S14T?4U%&:*^L.<****`"BBB
M@`HHID\ZVT32.RHB`LS,<!0!DDFAL#X\_P""X/QR@^%?[$NH:)%.L>J>.;N+
M2H$#8;RE833MC^[L38?>4#O7E_\`P;S_``=DT+X.^-O'%S"4;Q'J,6FVC,O+
M16R,S,/8O,5^L7M7R=_P4F_:0U#_`(*$_MG:?X<\&*^IZ/I=POA_P_%&<I?3
M/(!)<#T#O@`_\\XU)[BOV&_9>^!5A^S3\!O#'@?3B'@T"R2"24#'VB8Y>:7'
M^W*SM[;L5\G@Y?7,SEB5\%/1/S_JYT2]VGRO=GH-?%7_``6X_9Y\:?M%?`/P
MGIW@GP_>^(K[3]?%S<06VW?%%]GE7?AB,C<P''K7VK17T6-PL<31E1F[)F,)
M<KN?(_\`P1A^"/C#X`?LH:CH7C70;WP]JDGB&YNXK:Z*[VA:&W4/\I/!9&'/
MI7TG\7?A%X>^.OP_U'POXITV#5=$U6(QSP2#\0RGJK*<$,.00"*Z7-%*AA(4
MJ$:&Z2MJ$I7;9^)7[4G_``1S^+7P@^(VH:5X%T?5?&W@Z_<7-K<6KH'4+NV)
M<(6'[Q-Q`8#!!)&"2!^DO_!*+X3>)/@A^Q!X7\-^*])N=$UNSGOI)K.<J9(A
M)=RNN=I(Y5@?QKZ0HK@P.1T,+7=:DWKI;HO0N55RC9A7R]_P4!_X)B>%/VWM
M-@U$W3>'O&NGP>3:ZM%$'69!DB*=.-Z`DX((9<\''%?4-%>EB<-3KP=.JKIF
M<9-.Z/R_^$?P_P#VS/\`@GQ:#0=%T+3OB9X,M6/V>U2X%U'`N?\`ED"R3QCO
MMP5!/2O4K#_@I-^T+>J;5?V6O$AU`#!8W,T<.?JT/3\:^[J*\ZEE,Z*Y:-:2
MCVT=O2Z9;J7W1\B?`#XK?M8^/_BW87GC#X=>"O"O@>3Y+NTEOL7JH2/WB,K2
M%G4?PLJJ>0<<$?7=%%>AAJ#I1Y93<O6W^1,G?H>%_MR?L(>$_P!M_P"'D&E:
MV9=.UG3-\FE:O;H#/9.PP5(/WXVP-R$C.,@@@&OC#X)_!G]K3_@F?+>Z-X7\
M.:7\3_`UQ<&X6UMYMZHQZNB%EEB9@!D`.OU/-?J'17)B<JI5:BKQ;C/NOU[E
M1J-*W0^&%_X*<?'*.'RI/V5_&9O!QE9Y_+W?7[/T_&O)_CSX)_:[_P""D=G%
MX:U3P5I_PQ\#R3++/#=7(B$VU@5,Q)::0*>0JHJ[@"1QD?I_FBLZF53JQY*U
M:3B]UHK^MD"J6=TCYP_X)_\`_!.7PS^PMX2NC:W3:WXLUA%74]7DCV;U!R(8
MEYV1`\XR2QY)X`'T?117HX?#4Z$%3I*R1$I-N[/S8_X+>?LD?$K]H[XJ^!]0
M\$>$-3\1V>GZ5-;W,MIL(A<S;@IRP/(.:B_9X^/?[6O[/'P6\.^"K+]GR/4;
M/PY:"SAN)Y'6650206"RXS@XX]*_2RBO,GDR^L3Q-.I*,I;VMY>7D:*I[O*T
M?!'_``W)^V!_T;=9?]_I/_CM?6_[,?C/QE\0/@KI&K^/_#MMX3\4WHE>[TJ"
M0R+:`2NL8))/S%`K$9."V.U>@45UX;"5*4N:=5R\G;_(B4D^E@K@OVH/#5_X
MT_9M\?Z+I5L]YJ>K^'-0LK2!2`TTTEM(B(,\9+$#GUKO<CU%%=E2"G%Q?4E/
M6Y^47_!'C]B7XK?`3]K[_A(/&/@C5_#^CQZ)=P&ZNM@0R,T>U1AB<G![=J_5
MVBBN/+LOA@Z7L:;;5[ZEU*CD[L****[R#RK]M_P9JOQ&_9%^(F@:'8RZEK&K
MZ#=6UG;1$!YY&C(5!G`R3QR:^+O^"(?[)/Q)_9P^*?CG4/&_A'5/#EIJ&E00
M6TEUL`F<3%BJ[6)R!7Z345YU?+:=7$PQ3;3B6IM1<4%%%%>B0>!_\%.OAEK_
M`,8_V&O'7AKPOID^L:YJ<5I]FLX<"2;9>V\C`9('"(Q_"OF[_@AM^RM\0OV;
M=3^),_CCPMJ/AN/6(].2S-WL!N#&;DOM"D]-ZY/O7Z&T5YM7+(3Q4<6V[Q5O
M+K_F6IM1<0KP3]NG]@+PC^W'X(@L];:33->TM6.EZQ;H&FM21RC*>)(F/5"1
MZ@@\U[W1G/2NRO0A6@Z=173)C)IW1^6GPO\`V9OVOO\`@G%>W-GX"BTSXA^#
M6E,W]GI,LL#9))989&26)SW$9()Z[J]9TK_@I/\`M$0JMI>?LM>(Y=1(P6AF
MG2$G\86P,_[1^M?>5%>92RB5%<E"M*,>VCMZ73-/:)[H^+?AU\;_`-L+XE?$
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M/W:(6ZJA;(X^7M^H^:-P]16;R:-6:GBIN=M4G9+[D-56E:*L(JA!@``4M%%>
MR9!1110!RGQM^#6A_M`_"_6O"'B2V%WHVN6S6TZ<!T)P5D0]G1@&4]B`:_$K
M4]/^(_\`P1]_;+62,--';L3"[J4L_$>FLV2IZ\X`R.3'(N><`G]X*\I_:W_8
M_P#"'[9'PPE\-^*K5BT>9-/U"$`76F38XDC;TZ94\,.O8CQ,WRMXA*K1?+4C
ML_T9K2J*+L]F2_LG?M<>$/VPOA=;^)O"EZCC"I?6$C`76FS$<Q2KV]FZ,.17
MJ-?A/\5_@%\;O^"2GQE37]*O;VVT\R>7::]8QL^GZG'G(BG0Y4$@#,<G<94G
M`:OM;]D[_@O-X(^(5E:Z9\3K&3P9K9`1]1MT>XTRX;INP,R19/8A@.[5S8'/
MX7]AC5R5%WV?S*G0MK#5'Z!45S?PX^+_`(6^+NDB^\+^(]$\0VA`;S=/O8[A
M0#Z[2<'V/-=)D>HKZ&$U)7B[F`44V69((V=V5$49)8X`'K7@O[0/_!2[X-_L
MWV$_]M^,M-U#4H00NF:1(+Z[=A_"0A*H?^NC**BMB*=)<U222\V.,6W9'OA(
M`))``K\OO^"N_P#P58M;W2]3^%'PUU&.X-P&MO$.M6TF4"9P]I`PZD_==P<8
MRHSDX\9_;'_X*^?$3]L&\?P;X"TZ_P#"_AS59/LRV=B6GU75@QP$=D&0&Z>7
M'UY!9A7NG_!-3_@C"_AO4+#QY\8K*-[V`K<:;X:DQ(D#=1)==0S`\B(<`_>R
M?E'R^+S*MCY?5L!MUETL=$::A[TS6_X(G_\`!.F?X=6$?Q>\:6+6^MZE`5\.
MV4T>)+*WD7YKE@>DDBG"CLA)YWX'Z.TV*%85"J``!@=L4ZOH<OP-/"451I[+
M\7W,)S<G=A7SO^W]^W#=_L7:;X+:Q\.V?B"Y\8ZH=,47>H&RAM3A3O=PC?+E
MADXX`)]J^B*^6O\`@IO^QCXG_;"TOP`GAI_#C/X2UAM1NK;69)([>\CPG[L[
M$?()7!!'0FIS)UE0DZ'Q:6^]#A;F][8H?&K]O[QI^SOX)GU_Q%X<^%.H6MKA
MGL])\?[[Z89`Q%%+:IYC<_=4Y.#7T+\!_BR/CE\)-"\5KHVK>'QKEJMT+#4H
MA'<VX).`P!/!QD'NI4X&<5\P?$[]C3QG\1O!>H:3;?!_]G/0+N]@:*'4D:>6
M:R8\>;&$M(VWKU4AQ@@'M@^W_L1?L]Z]^S%\";/PIXC\8ZAXVU*WF><WMR&"
MVZMC$$>XEO+7!QN)/S'H,`<N$EB?;-33Y&O+1_@_P')*VAZ_63X[\3_\(9X+
MU?5Q#]I_LNRFN_*W;?,\N-GVY[9QC.#6M6+\1_#\WBWP%K>DV[(D^J6$]I&S
MYVHSQLH)QVR:]6HI<KY=S,\Q_8-_:PE_;-_9[L_'$^BQZ!)<W=Q:M:)<FX"^
M4^W=N*KUZXQ7M%>!?\$VOV8->_9$_9AL?!?B.[TV\U2VOKFZ>2Q=WAVRR94`
MNJDD#KQ7OM88)U/80=;XK*_J5-J_N[!7S/-_P4`O?B?\?/$7PY^%'A"/Q=JG
M@]C'KNK:CJ7]G:7ITH<H8PRQR22,'5E^5.J-C(!-?3%?)&B_L->+_P!FS]IC
MQ=\1?A)J>@7MCX\D:?6O#GB`RP1"8R-+YD%S$KLOSNY"LA`#D<\8C&NM>'LM
MK^];>WE\PC;J=;\6_P!I+XP?L^>"+[Q5XB^&WA;7_#^DPFYU#_A'_$4K7MK"
MHR\HCGMT60*N20&!P.E>H?LX?M#>'?VH_A+I?C/PO/+-I.J*P594V302*Q5X
MW7)PRL,<$@\$$@@GR7X[^$_CW^T%\+=9\'QZ/\._!%IXAM)-/O=377;K59XX
M)%*R>5$+6$;BI(&YL#->@?L;?LN:5^Q]\!-)\#:5>W.I)8%Y[F\G4(]U/(Q9
MWVCA1G@+DX`')/)QH3K.OI?DMU[^74;2L>J5RWQ5U7Q?I/A^&3P7I.@ZSJC3
MA9(=6U*6Q@6+:V6#QQ2DMG:-NT#!)SQ@]317I3CS*U[$'Q\?V]/BN/VLA\&O
M^%;^"3XI.F_VK]H_X2BX^PB';N^_]DW[NV-GXU])_"76/&NKZ3=-XWT;P[HE
M\DV+>/2-3EOXI(]OWF:2&(JV[(P`>._:O%6_9`\1G_@IHOQG%YI)\-#PY_9/
MV;S'%YYVW;G;MV[<<YW9]J^F*\[`TZUY.K)Z-VVU73H5)KH%<Q\:?B'_`,*A
M^#_BGQ7]E-]_PC.CW>JFVW[#<>1`\NS=@XW;,9P<9Z5T]<=^T#X#N_BE\"?&
MGABPD@AOO$>A7VEV\DQ(CCDGMWB5FP"=H9@3@$XKNK<W(W'>SM]PEN?.?[/?
M_!0GQO\`M'?"NQ\6:5X9^%FDV-^\J);:OXZ>VNT,;E"606;8!*DCGD8/>OI/
MX0>(O$7BCPFM[XFT_P`/Z=>S2%H%T?5'U&UEA(!5Q*T47).[@*1C')SQ\=?L
MQ_L`^//V?O@_I_A?4_AA\!/&=Y92S2/JNHW$IN;@22,X#%K)B=H;:.>BBOK;
MX"V7BC2?"36'B7P_X2\."Q*PZ?9^'KN2>U2`*`!AX8MA!R`J@C`'3I7FY=.N
MU%5[WMK?:_Y?B5-*_NG<T$A022`!13)X%N8FC<!D<%6!Z$'J*]=D'S+X._X*
M#WW[1_Q"U[P_\&/!L7B^S\,R"#4O$.J:F--TJ.1BP"Q%8Y)9L[&(*H!@9Z$$
M^E>"?%/Q>?Q?:6WB3PEX$AT2?/GWNF^(;F2>WXX`ADM5WDGC[P_Q\4^!_P"Q
M!\0/V'?%OB-OA'JGA77?!GB6[^W2:!XD\^VGL)0-O[FZB5]PVX'SQG@#OEC[
M7X1UWXQ:MXFL!KOAOX?:+HJN?MAM=<NK^Z9-I_U8-M$H.<?>)XS7CX25=J^(
M;4K[)>[\M#1\NR/4Z***]@S.-_:%^*C?`[X'>+O&*V:ZBWAC2+K4Q:F3RQ<&
M&)G";L'&2,9P:X7]DS]M;P[^TA\`/#_C+4+W0?#=[K"2F;39-5B=[5DFDBP2
MVT\A`W*CAA]:Z[]J'X:7WQH_9U\;^$=,FMX-0\2Z)=Z9;R7!(B226)D4L0"0
MN3S@'BO+/V,_V`O#/P4_9N\,^&/&7A/P/KWB73(IA?7PTR*Y^T.\\D@/F21A
MVPCJN2/X?2O,J2Q'UE*G\'+UVO<M)<MV6/!/[?%IX]_;QU7X-Z;IEA>6&FZ(
M-5&MVVH+,LK[8F,6Q5QP)<9W9R.E?1-?*GPS_8)O/A9_P4;UGXK:/;^&M(\%
M7_A\:;#IMA&8)HY]L(9O+5`@!\LG(;)R.*^JZVP+K.,O;K7F=O3H*5M+!111
M7:2%%%%`'!_M,?&%_P!GWX!^*_&L>GKJC^&M.EOA:M+Y0G*#.W=@XSZX-5/V
M3/CL_P"TQ^SMX6\=2::ND2>([4W#6:S><(")'3&_`S]W/0=:/VN?A-J'QV_9
MG\:^#M*FMK?4O$>E365M)<EEA1V7`+%02!GT!JC^Q/\`!74_V=/V6/!W@C69
M[.ZU3P]9M;W$MJS-"[&5W^4L`2,,!R!7"G5^MVM[G+^-RK>[<]5HHHKN)/A[
MPU_P67L[?XS>*=(\6^![W0O!7AOQ#-X<F\46UR;N&SN%ED2(W$80&-)!&WS`
MG!!'.":];_;"_;PM_P!F;1_AQJ.E:3:>*]/^(&M0Z9%<0WX2*.*0*1,C*K!\
MALCH/>N9_8]_8+U'X1^+/CI_PG"^'=?\.?%/7#J%O9(&G4P-+<N4F5T`!Q,G
M`+<J3GI7D?Q=_P""0_C"'Q?X;TSX?^,;0?##2/$5OXACT'7)97ET65&/F):R
M!6+1LI/R,1@\DD_-7SG/F,:#=KMOR37O6^::^XV3A<_0BBBBOHD8GS]^T'^W
MUI'PA^,VC?#'PYH&H>.?B5KRA[?1[.=+:*V0HS^9<3O\L:[$9N`QVKG`R,ZI
M\9?'R.W2X_X0/X:2%L%K0>*KH2H#VWFSVDCZ8KBOV@_V#-8UG]J+3?C;\-O$
M=AH7CVSMA9WEIJUJUQIFJQ>48L/L(>-O+(7<N>$7@$$GN+;Q)\>Y;402>#_A
M;!<@8-W_`,)+>/#G^]Y7V,-CVW_C7DQE6]I-5KI7TLM+?<]>YJK65CV'2KBX
MN=/@>[ABM[IHU,T<<AD2-R/F56(4L`<@'`SZ#I5BJFA-=MI%L;];=+XQ)]H$
M!8Q"3'S;"<$KG.,\XJW7K)F04444P"BBB@#/\4>%=.\:Z)<Z9JUE::EIUY&8
MI[:YB66&93U5E8$$>Q%?#O[3'_!!GX;_`!/NKC4O`NI7_@+49R7-LB_;--+=
M>(V(>/)_NOM'9>U?>5%<6+R^AB8\M:*?Y_>5&;B[H_%/QG_P1)_:#^$NJM<^
M&$TGQ!Y1+17&CZN+68>AQ-Y1!^A-9D?[/W[:_AY?LL,/QCC2/@+!KD[H/H5F
M(_*OV_HKQWPO07\.I**\F:JN^Q^'D_[`/[7?QPVP:WI/C2]MW/S-KWB%!&/J
MLLQ;\E->M_!'_@WK\6:M=PW/Q!\9:5HMJ3N>UT>-KRY8==OF.$1#UY`>OUHH
MITN%\)%\U1N?J]`]O+IH>*_LO?\`!/[X7_LB62GPCX?C&JE-DNKWK"XU"88Y
M_>$?(#W5`J^U>U445[]&A3I14*:LO(Q;;=V%%%%:B"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
C`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
